Latest stories on MESO
Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)
Business Insider50 · neutralgeneral
Mesoblast: Ryoncil Helps Fund Rexlemestrocel-L For Back Pain
Seeking Alpha63 · neutralproduct/pr
Mesoblast GAAP EPS of -$0.04 beats by $0.08, revenue of $120.25M misses by $65.62M
Seeking Alpha48 · neutralearnings
Mesoblast wins FDA nod for new potency assay for Ryoncil
Seeking Alpha67 · bullishproduct/pr
Cantor Fitzgerald reiterates Mesoblast stock rating on adult trial focus
Investing.com Analyst Ratings55 · neutralanalyst
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
StockTitan73 · bullishproduct/pr
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
GlobeNewswire73 · bullishproduct/pr
Mesoblast price target raised to $39 from $35 at Piper Sandler
The Fly61 · neutralanalyst
Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Mesoblast Reports Substantial Revenue Growth to US$120M
GlobeNewswire67 · bullishearnings
Mesoblast Reports Substantial Revenue Growth to US$120M
StockTitan67 · bullishearnings
Mesoblast H2 Earnings Call Highlights
Yahoo Finance58 · neutralearnings
Mesoblast Q2 Earnings Preview
Seeking Alpha50 · neutralearnings
Mesoblast Financial Results and Corporate Update Webcast
GlobeNewswire50 · neutralgeneral
Mesoblast Financial Results and Corporate Update Webcast
Business Insider50 · neutralgeneral
Mesoblast shares jump as Phase 3 chronic back pain trial completes patient treatment
InvestorsHub63 · neutralproduct/pr
Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial
The Fly59 · neutralproduct/pr
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
Business Insider67 · bullishproduct/pr
Mesoblast Limited 2026 Q4 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Mesoblast Posts US$115m First-Year Ryoncil Sales and Advances Late-Stage Cell Therapy Pipeline
TipRanks63 · neutralproduct/pr
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
StockTitan59 · neutralearnings
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain | MESO Stock News
StockTitan63 · neutralproduct/pr
Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesis
Seeking Alpha67 · bullishproduct/pr
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
Business Insider55 · neutralproduct/pr
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 | MESO Stock News
StockTitan59 · neutralearnings